Phathom prices public offering of 11.125M shares at $11.75/share for ~$130.7M gross

Phathom Pharmaceuticals, Inc.

Offering of 11,125,000 shares at $11.75/share; gross proceeds ~$130.7M.
Underwriters have 30-day option to purchase up to 1,668,750 additional shares.
Net proceeds ~$122.4M ($140.8M if option exercised) to fund vonoprazan clinical dev., pre-commercial, and working capital.
Offering expected to close May 26, 2023; Jefferies and Evercore ISI act as joint bookrunners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.